Profusa Expands EU CLTI Coverage to 200,000 Cases and Raises Conversion Floor to $0.35
Profusa partnered with MedSell to commercialize Lumee™ Oxygen across 200,000 annual CLI cases in France, joining its EU network and targeting $0.5–$2M revenue in 2026 and $9–$13M in 2027. The company restructured its Senior Secured Convertible Notes, raising the conversion floor to $0.35 and eliminating mandatory amortization to reduce dilution.
1. Profusa Expands French Commercial Footprint with MedSell
Profusa announced a new distribution agreement with MedSell to commercialize its Lumee Oxygen tissue monitoring device in France, targeting both hospital and outpatient wound care clinics. MedSell brings tailored market-entry support and will leverage its existing network to address complex and chronic wound patients with Critical Limb Threatening Ischemia (CLTI). This partnership builds on Profusa’s presence in Spain, Germany, the Benelux countries, Austria, the United Kingdom and Scandinavia, extending coverage to roughly 200,000 annual CLTI cases across the European Union.
2. Collaboration with Leading Paris Vascular Center Accounts for 8% of French CLTI Cases
The MedSell agreement complements an ongoing collaboration with Professor Yann Gouëffic of the Vascular Center at Groupe Hospitalier Paris Saint Joseph, whose practice and clinical studies represent approximately 8% of all CLTI cases in France. Professor Gouëffic is integrating Lumee Oxygen monitoring into revascularization procedures, endovascular and open surgical workflows, and home monitoring studies, further validating the device’s clinical utility across the entire treatment pathway.
3. Progressive Revenue Milestones Through 2030
Profusa projects initial European commercial launch in the second quarter of 2026, with forecasted revenues of $0.5 million to $2 million for that year and $9 million to $13 million in 2027. The company’s long-term plan targets $200 million to $250 million in annual revenue by 2030, driven by expanding adoption of its continuous oxygen perfusion monitoring platform in both clinical and home settings, and leveraging recent presentations of U.S. clinical trial data at major vascular conferences.
4. Balance Sheet Recapitalization Reduces Dilution and Extends Flexibility
In parallel with its commercial initiatives, Profusa restructured its Senior Secured Convertible Notes to enhance repayment flexibility and minimize share dilution. Key amendments include eliminating mandatory amortization payments originally slated for early 2026, raising the conversion floor price from $0.10 to $0.35, and increasing mandatory Equity Line of Credit payments from 33% to 50% for any new registration statements. These changes defer the final payment to the 18-month maturity date and free up cash flow to accelerate inventory build, expanded partnerships and ongoing research efforts.